ApprovedFDA approval

Icotyde (icotrokinra)

Janssen Biotech (Johnson & Johnson) (JNJ)

Marketer take

An oral IL-23 receptor-blocking peptide for moderate-to-severe psoriasis in patients 12 and older, which challenges injectable IL-23 and IL-17 biologics and Sotyktu on convenience with dermatologists and payers.

Sponsor company
Janssen Biotech (Johnson & Johnson) (JNJ)
Indication
To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
Therapeutic area
Immunology, Dermatology
Event
FDA approval
Date
Mar 17, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move